Navigation Links
Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results

rry D. Quart, President and CEO. "We made significant progress in advancing our business and in the development of our pipeline, achieving several important milestones." These include:

-- Completion of Phase 1 single-ascending-dose, multiple-ascending-dose,

food-effect, and drug-interaction clinical studies of RDEA806, our lead

non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV, in

August of 2007;

-- Presentation of four posters describing the favorable results of

preclinical and Phase 1 clinical trials with RDEA806 during the 47th

Annual Interscience Conference on Antimicrobial Agents and Chemotherapy


-- Completion, submission and FDA approval of our investigational new drug

application (IND) for our lead mitogen-activated ERK kinase (MEK)

inhibitor, RDEA119, allowing us to proceed to Phase 1 clinical trials

in advanced cancer patients; and

-- Presentation of RDEA119 preclinical data, showing favorable properties,

including oral dosing, excellent selectivity and low central nervous

system (CNS) penetration, at the American Association of Cancer

Research (AACR), National Cancer Institute (NCI) and European

Organization for Research and Treatment of Cancer (EORTC) International

Conference on Molecular Targets and Cancer Therapeutics.

"We are well positioned for continued progress and success with our development programs in viral diseases, cancer and inflammatory diseases and are working to achieve several milestones in the next few months," added Dr. Quart. These include:

-- Initiation of a Phase 2a proof-of-concept trial with our lead NNRTI,


-- Assessing a next-generation NNRTI from our follow-on program in a

first-in-human micro-dosing study;

-- Initiation of a Phase 1 advanced cancer clinical study of our lead MEK

inhibitor, RDEA119;'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
4. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
5. Pressure BioSciences, Inc. Issued First Patent in Canada
6. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Pressure BioSciences, Inc. Provides Corporate Update
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
(Date:7/29/2014)... Oregon , July 29, 2014 ... "Global surgical equipment market (types, applications and geography) - ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", ... to reach $12.1 billion by 2020 registering a CAGR ... to the breakthrough achieved by the electro surgical devices ...
(Date:7/29/2014)... Hershey, PA & Rockville, MD (PRWEB) July 29, ... Immunomic Therapeutics, Inc. (ITI), a vaccine pioneer in ... the financial services firm Newport Coast Securities, Inc. ... , ITI is commercializing LAMP-vax technology, a breakthrough ... $25B+ vaccines and immunotherapy market. The company exclusively ...
(Date:7/29/2014)... Hill, South Carolina (PRWEB) July 29, 2014 ... with teams of people where cell phone masts or other ... iPhones up to 100 feet away without the need for ... to target longer ranges. , The new app has launched ... of US homes are at very high risk of being ...
(Date:7/29/2014)... 29, 2014 The first product launch ... generation approach to robotics. What sets Droidles completely apart ... technology that allows them to communicate, share code with ... the internet. , “The invention is the system,” said ... Droidles a life of their own, both physically and ...
Breaking Biology Technology:Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on 2
... , DURHAM, N.C., Aug. 12 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... 10-K for the fiscal year ended April 30, 2009. In addition to being available ... v , the 10-K can be downloaded from the company website at ... the Investors page. , , For the year ended April 30, ...
... , , LYNBROOK, N.Y., Aug. 12 ... company developing first in class collagenase-based products, today announced its ... , , "We were very pleased ... with Priority Review for XIAFLEX(TM) for the treatment of Dupuytren,s ...
... , , SAN DIEGO, Aug. 12 ... results for the three and six months ended June 30, 2009. , ... have the capital to complete and submit a New Drug Application (NDA) ... said Brian M. Culley, Principal Executive Officer at ADVENTRX. "Our financial ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 2Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 2ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 3ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 4ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 5ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 7
(Date:7/29/2014)... affects 1 in 100,000 people characterized by a loss ... remains unknown, a new study by a team of researchers ... Germany and other European institutions confirms for the first time ... 6 July in Nature Genetics , is an important ... a sphincter in the lower esophagus opens, allowing food to ...
(Date:7/29/2014)... UC San Francisco is the first to show that ... accelerate cellular aging, these negative effects may be reduced ... , "The study participants who exercised, slept well ... ones who didn,t maintain healthy lifestyles, even when they ... Puterman, PhD, assistant professor in the department of psychiatry ...
(Date:7/28/2014)... discovery of two additional coral communities showing signs of damage ... of the 2010 spill in the Gulf of Mexico. The ... professor of biology at Penn State University. A paper describing ... in the Gulf of Mexico will be published during the ... of the journal Proceedings of the National Academy of ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... it may be more lyrical than useful when discussing ... of the Sackler Institute of Comparative Genomics at the ... the University of Colorado at Boulder. The team used ... the populations of small mammals living on mountaintops in ...
... on a nano scale how can you see what you ... Biological Sciences research Council (BBSRC) fellow has made a significant ... With new research published today (13 August) in ... School of Pharmacy (University of London) and the University of ...
... also available in German . Halle/Saale, ... plant species could lose parts of its current range, ... Environmental Research (UFZ), the Potsdam Institute for Climate Impact ... Species distributions will be rearranged as a result of ...
Cached Biology News:Sky islands: metaphor or misnomer? 2Scientists overcome nanotech hurdle 2Scientists overcome nanotech hurdle 3Climate change threatens 1 in 5 plant species 2
Prepared in distilled water....
... RiboGreen RNA Quantitation Kit is one ... for the quantitation of RNA in ... 1000-fold more sensitive than absorbance measurements. ... be detected with fluorescence microplate readers ...
Request Info...
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: